FDA Approves Remodulin for Pulmonary Hypertension

Author:
Date Published: June-2010
Source: Bio-Medicine

According to a notice distributed by the agency, the US Food and Drug Administration (FDA) has approved United Therapeutics Corp.'s pulmonary arterial hypertension therapy Remodulin (treprostinil sodium).


AddThis Social Bookmark Button